Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Jul;45(1):261–266. doi: 10.1128/iai.45.1.261-266.1984

Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.

F M Audibert, G Przewlocki, C D Leclerc, M E Jolivet, H S Gras-Masse, A L Tartar, L A Chedid
PMCID: PMC263310  PMID: 6735468

Abstract

Adjuvant-active murabutide (N-acetylmuramyl-L-alanyl-D-glutamine-alpha-n-butyl ester), devoid of the side effects of muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine), was administered in saline with natural and synthetic hepatitis B surface antigens (HBsAgs). This derivative enhanced the antibody responses against natural HBsAg. The persistence of high antibody titers was the same in the murabutide-treated group as in the alum-treated group. A synergistic enhancement of the antibody was obtained when both adjuvants were administered together. Cell-mediated immunity to HBsAg, tested by the proliferative response of lymph node cells to the antigen, was also shown to be induced in mice treated with alum-associated murabutide. When administered with natural HBsAg, murabutide produced titers of total antibodies as high as did alum but lower titers of specific immunoglobulin E. High levels of antipeptide antibodies were obtained when a synthetic fragment [HBsAg(99-121)] conjugated to a toxoid carrier was administered with murabutide in saline.

Full text

PDF
261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamowicz P., Yaniv M., Platel A., Muller L., Croissant O., Prunet P. Caractéristiques biochimiques d'un vaccin contre l'hépattie B. C R Seances Acad Sci III. 1981 Jan 26;292(4):373–378. [PubMed] [Google Scholar]
  2. Audibert F., Chedid L., Hannoun C. Augmentation de la réponse immunitaire au vaccin grippal par un glycopeptide synthétique adjuvant (N-acétyl muramyl-L-alanyl-D-isoglutamine). C R Acad Sci Hebd Seances Acad Sci D. 1977 Sep 12;285(4):467–470. [PubMed] [Google Scholar]
  3. Audibert F., Chedid L. Recent advances concerning the use of muramyl dipeptide derivatives as vaccine potentiators. Prog Clin Biol Res. 1980;47:325–338. [PubMed] [Google Scholar]
  4. Audibert F., Chédid L., Lefrancier P., Choay J. Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol. 1976 Feb;21(2):243–249. doi: 10.1016/0008-8749(76)90053-8. [DOI] [PubMed] [Google Scholar]
  5. Audibert F., Jolivet M., Chedid L., Arnon R., Sela M. Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A. 1982 Aug;79(16):5042–5046. doi: 10.1073/pnas.79.16.5042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Audibert F., Przewlocki G., Lefrancier P., Choay J., Chedid L. Renforcement de l'activité d'un vaccin contre l'hépatite virale de type B par association avec le murabutide. C R Seances Acad Sci III. 1982 Nov 22;295(10):611–614. [PubMed] [Google Scholar]
  7. Bhatnagar P. K., Papas E., Blum H. E., Milich D. R., Nitecki D., Karels M. J., Vyas G. N. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc Natl Acad Sci U S A. 1982 Jul;79(14):4400–4404. doi: 10.1073/pnas.79.14.4400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chedid L. A., Parant M. A., Audibert F. M., Riveau G. J., Parant F. J., Lederer E., Choay J. P., Lefrancier P. L. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun. 1982 Feb;35(2):417–424. doi: 10.1128/iai.35.2.417-424.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chedid L., Audibert F., Lefrancier P., Choay J., Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472–2475. doi: 10.1073/pnas.73.7.2472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chou P. Y., Fasman G. D. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol. 1978;47:45–148. doi: 10.1002/9780470122921.ch2. [DOI] [PubMed] [Google Scholar]
  11. Cryz S. J., Jr, Friedman R. L., Pavlovskis O. R., Iglewski B. H. Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: biological, chemical, and immunochemical studies. Infect Immun. 1981 May;32(2):759–768. doi: 10.1128/iai.32.2.759-768.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dreesman G. R., Sanchez Y., Ionescu-Matiu I., Sparrow J. T., Six H. R., Peterson D. L., Hollinger F. B., Melnick J. L. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature. 1982 Jan 14;295(5845):158–160. doi: 10.1038/295158a0. [DOI] [PubMed] [Google Scholar]
  13. Dudley F. J., Giustino V., Sherlock S. Cell-mediated immunity in patients positive for hepatitis-associated antigen. Br Med J. 1972 Dec 30;4(5843):754–756. doi: 10.1136/bmj.4.5843.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Durette P. L., Dorn C. P., Jr, Friedman A., Schlabach A. Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide. J Med Chem. 1982 Sep;25(9):1028–1033. doi: 10.1021/jm00351a005. [DOI] [PubMed] [Google Scholar]
  15. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  16. Fattovich G., Alberti A., Crivellaro C., Pontisso P., Noventa F., Realdi G. Cellular immunity to the hepatitis B virion in acute hepatitis type B. Clin Exp Immunol. 1983 Sep;53(3):645–650. [PMC free article] [PubMed] [Google Scholar]
  17. Gerety R. J., Hoofnagle J. H., Barker L. F. Humoral and cell-mediated immune responses to two hepatitis B virus antigens in guinea pigs. J Immunol. 1974 Oct;113(4):1223–1229. [PubMed] [Google Scholar]
  18. Ibrahim A. B., Vyas G. N., Perkins H. A. Immune response to hepatitis B surface antigen. Infect Immun. 1975 Jan;11(1):137–141. doi: 10.1128/iai.11.1.137-141.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ibrahim A. B., Vyas G. N., Prince A. M. Studies on delayed hypersensitivity to hepatitis B antigen in chimpanzees. Clin Exp Immunol. 1974 Jun;17(2):311–318. [PMC free article] [PubMed] [Google Scholar]
  20. Jolivet M., Audibert F., Beachey E. H., Tartar A., Gras-Masse H., Chedid L. Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant. Biochem Biophys Res Commun. 1983 Dec 16;117(2):359–366. doi: 10.1016/0006-291x(83)91208-1. [DOI] [PubMed] [Google Scholar]
  21. Laiwah A. A., Chaudhuri A. K., Anderson J. R. Lymphocyte transformation and leucocyte migration-inhibition by Australia antigen. Clin Exp Immunol. 1973 Sep;15(1):27–34. [PMC free article] [PubMed] [Google Scholar]
  22. Lefrancier P., Derrien M., Jamet X., Choay J., Lederer E., Audibert F., Parant M., Parant F., Chedid L. Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides. J Med Chem. 1982 Jan;25(1):87–90. doi: 10.1021/jm00343a018. [DOI] [PubMed] [Google Scholar]
  23. Lerner R. A., Green N., Alexander H., Liu F. T., Sutcliffe J. G., Shinnick T. M. Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3403–3407. doi: 10.1073/pnas.78.6.3403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Löwy I., Leclerc C., Chedid L. Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives. Immunology. 1980 Mar;39(3):441–450. [PMC free article] [PubMed] [Google Scholar]
  25. Milich D. R., Alexander H., Chisari F. V. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). III. Circumvention of nonresponsiveness in mice bearing HBsAg nonresponder haplotypes. J Immunol. 1983 Mar;130(3):1401–1407. [PubMed] [Google Scholar]
  26. Mota I., Wong D. Homologous and heterologous passive cutaneous anaphylactic activity of mouse antisera during the course of immunization. Life Sci. 1969 Aug 15;8(16):813–820. doi: 10.1016/0024-3205(69)90099-x. [DOI] [PubMed] [Google Scholar]
  27. Ovary Z., Caiazza S. S., Kojima S. PCA reactions with mouse antibodies in mice and rats. Int Arch Allergy Appl Immunol. 1975;48(1):16–21. doi: 10.1159/000231289. [DOI] [PubMed] [Google Scholar]
  28. Siddiqui W. A., Taylor D. W., Kan S. C., Kramer K., Richmond-Crum S. M., Kotani S., Shiba T., Kusumoto S. Vaccination of experimental monkeys against Plasmodium falciparum: a possible safe adjuvant. Science. 1978 Sep 29;201(4362):1237–1239. doi: 10.1126/science.99814. [DOI] [PubMed] [Google Scholar]
  29. Tong M. J., Wallace A. M., Peters R. L., Reynolds T. B. Lymphocyte stimulation in hepatitis B infections. N Engl J Med. 1975 Aug 14;293(7):318–322. doi: 10.1056/NEJM197508142930702. [DOI] [PubMed] [Google Scholar]
  30. Webster R. G., Glezen W. P., Hannoun C., Laver W. G. Potentiation of the immune response to influenza virus subunit vaccines. J Immunol. 1977 Dec;119(6):2073–2077. [PubMed] [Google Scholar]
  31. Woodard L. F., Toone N. M., McLaughlin C. A. Comparison of muramyl dipeptide, trehalose dimycolate, and dimethyl dioctadecyl ammonium bromide as adjuvants in Brucella abortus 45/20 vaccines. Infect Immun. 1980 Nov;30(2):409–412. doi: 10.1128/iai.30.2.409-412.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. de Gast G. C., Houwen B., Nieweg H. O. Specific lymphocyte stimulation by purified, heat-inactivated hepatitis-B antigen. Br Med J. 1973 Dec 22;4(5894):707–709. doi: 10.1136/bmj.4.5894.707. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES